Compounds > quinuclidines
Page last updated: 2024-08-18

quinuclidines and 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one

quinuclidines has been researched along with 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's6 (66.67)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Bergman, J; Bykov, VJ; Selivanova, G; Stridh, H; Westman, J; Wiman, KG; Zache, N1
Shen, J; Stridh, H; Vakifahmetoglu, H; Wiman, KG; Zhivotovsky, B1
Bykov, VJ; Eckhardt, I; Rökaeus, N; Shen, J; Wilhelm, MT; Wiman, KG1
Chang, H; Jiang, H; Reece, D; Saha, MN; Yang, Y1
Omar, SI; Tuszynski, J1
Crown, J; Duffy, MJ; Gallagher, WM; Kiely, M; Kiely, PA; McGowan, PM; Murray, A; O'Connor, DP; O'Donovan, N; Synnott, NC1
Andrade, SMMV; Carvalho, RS; Costa, CL; Costa, DCF; Ferretti, GDS; Rangel, LP; Silva, JL1
Galoczová, M; Vojtěšek, B; Zatloukalová, P1
Abrahmsén, L; Degtjarik, O; Diskin-Posner, Y; Golovenko, D; Rozenberg, H; Shakked, Z1

Reviews

1 review(s) available for quinuclidines and 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one

ArticleYear
Prima-1 and APR-246 in Cancer Therapy.
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2018,Winter, Volume: 31, Issue:Suppl 2

    Topics: Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Humans; Neoplasms; Quinuclidines; Tumor Suppressor Protein p53

2018

Other Studies

8 other study(ies) available for quinuclidines and 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one

ArticleYear
PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.
    Oncogene, 2005, May-12, Volume: 24, Issue:21

    Topics: Adenocarcinoma; Animals; Apoptosis; Aza Compounds; Bone Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Interactions; Drug Resistance, Neoplasm; Genes, p53; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Osteosarcoma; Quinuclidines; Transplantation, Heterologous; Tumor Cells, Cultured

2005
PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2.
    Oncogene, 2008, Nov-20, Volume: 27, Issue:51

    Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Caspase 2; Caspase 3; Caspase 9; Caspase Inhibitors; Cytochromes c; Drug Evaluation, Preclinical; Enzyme Activation; Enzyme Inhibitors; Genes, p53; Humans; Membrane Potential, Mitochondrial; Mitochondria; Quinuclidines; Tissue Distribution; Tumor Cells, Cultured

2008
PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.
    Oncogene, 2010, Dec-09, Volume: 29, Issue:49

    Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Gene Expression; Humans; Mutation; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Quinuclidines; Trans-Activators; Transcription Factors; Tumor Protein p73; Tumor Suppressor Proteins

2010
PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Dexamethasone; DNA-Binding Proteins; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Multiple Myeloma; Neoplasms, Experimental; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Quinuclidines; Tumor Protein p73; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2013
Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties.
    Chemical biology & drug design, 2015, Volume: 86, Issue:2

    Topics: Alkylation; Amifostine; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Drug Evaluation, Preclinical; Ellipticines; Heterocyclic Compounds, 4 or More Rings; Humans; Kinetics; Ligands; Mercaptoethylamines; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Mutation; Oxepins; Protein Binding; Pyrimidines; Quinuclidines; Tumor Suppressor Protein p53

2015
Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    International journal of cancer, 2017, Jan-01, Volume: 140, Issue:1

    Topics: Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Mutation; Quinuclidines; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53

2017
p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
    The Journal of biological chemistry, 2019, 03-08, Volume: 294, Issue:10

    Topics: Amyloid; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Mutant Proteins; Mutation; Protein Aggregates; Protein Multimerization; Protein Structure, Secondary; Quinuclidines; Tumor Suppressor Protein p53

2019
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ).
    Nature communications, 2021, 12-03, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Crystallography, X-Ray; Humans; Loss of Function Mutation; Neoplasms; Protein Domains; Quinuclidines; Recombinant Proteins; Tumor Suppressor Protein p53

2021